BIOMARIN PHARMACEUTICAL INC reports

Company location: Novato, CA
Fiscal year end: 31 December

BIOMARIN PHARMACEUTICAL INC has filed 2,740 SEC EDGAR filings since 04 May 1999

Filter by type:
10-K
10-Q
8-K
SC13D
SC13G

SEC filing history

Showing 401-425 of 1,000 matching filings.

Per page

25

Current page

17

4

FORM 4

Filing date: 06 May 2022
Reporting date: 29 Apr 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 06 May 2022
Reporting date: 29 Apr 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

8-K File 000-26727

8-K

Filing date: 05 May 2022
Reporting date: 05 May 2022
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

4

FORM 4

Filing date: 04 May 2022
Reporting date: 02 May 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 04 May 2022
Reporting date: 29 Apr 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 02 May 2022
Reporting date: 28 Apr 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

10-Q File 000-26727

10-Q

Filing date: 29 Apr 2022
Reporting date: 31 Mar 2022
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

4

FORM 4

Filing date: 27 Apr 2022
Reporting date: 25 Apr 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

8-K File 000-26727

8-K

Filing date: 27 Apr 2022
Reporting date: 27 Apr 2022
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

4

FORM 4

Filing date: 20 Apr 2022
Reporting date: 18 Apr 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 18 Apr 2022
Reporting date: 14 Apr 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 18 Apr 2022
Reporting date: 14 Apr 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 14 Apr 2022
Reporting date: 13 Apr 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

DEFA14A File 000-26727

DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS

Filing date: 12 Apr 2022
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

DEF 14A File 000-26727

DEFINITIVE PROXY STATEMENT

Filing date: 12 Apr 2022
Reporting date: 24 May 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 31 Mar 2022
Reporting date: 29 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

UPLOAD

UPLOAD filing

Filing date: 29 Mar 2022
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 24 Mar 2022
Reporting date: 22 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 23 Mar 2022
Reporting date: 21 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 17 Mar 2022
Reporting date: 15 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 17 Mar 2022
Reporting date: 15 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 17 Mar 2022
Reporting date: 15 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 17 Mar 2022
Reporting date: 15 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 17 Mar 2022
Reporting date: 15 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 17 Mar 2022
Reporting date: 15 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .